

## anti-inflammatoxy and immuno-therapy - all results

Treatment	Number of studies	Demonstrated or suggested results	Inconclusive results	Uncertain results	Safety results
Immunosuppressants drugs	3 studies <sup>1</sup>	demonstrated 13			
Immunostimulants drugs	2 studies <sup>2</sup>		inconclusive results for : death D28 ; deaths ; viral clearance (time to event analysis only)	suggested 6.5-fold increase in radiologic improvement (14-day) but the degree if certainty is unassessable suggested 90	
leflunomide	1 study <sup>3</sup>		-		

Uncertain results are statistically significant results but obtain in trial with high risk of bias.

Demonstrated results are significant results obtained on the primary endpoint of a trial at low risk of bias or with some concerns.

## Notes

<sup>1</sup>RECOVERY, 2022 (NCT04381936) ; BACC Bay Tocilizumab Trial, 2020 (NCT04356937) ; TOCOVID, 0 (NCT04332094)

<sup>2</sup>LIFESAVER, 2021 (NCT04374526) ; Cai -FAVIPRAVIR, 2020 (ChiCTR2000029600)

<sup>3</sup>Wang, 2020 (ChiCTR2000030058)